PL367267A1 - Antineoplastic combinations - Google Patents

Antineoplastic combinations

Info

Publication number
PL367267A1
PL367267A1 PL02367267A PL36726702A PL367267A1 PL 367267 A1 PL367267 A1 PL 367267A1 PL 02367267 A PL02367267 A PL 02367267A PL 36726702 A PL36726702 A PL 36726702A PL 367267 A1 PL367267 A1 PL 367267A1
Authority
PL
Poland
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
Prior art date
Application number
PL02367267A
Other languages
English (en)
Polish (pl)
Inventor
Gary Dukart
James Joseph Gibbons Jr.
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of PL367267A1 publication Critical patent/PL367267A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02367267A 2001-06-01 2002-05-29 Antineoplastic combinations PL367267A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29519001P 2001-06-01 2001-06-01
US29523601P 2001-06-01 2001-06-01

Publications (1)

Publication Number Publication Date
PL367267A1 true PL367267A1 (en) 2005-02-21

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02367267A PL367267A1 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Country Status (17)

Country Link
EP (1) EP1392286A2 (no)
JP (1) JP2004532883A (no)
KR (1) KR100875611B1 (no)
CN (1) CN100496485C (no)
AU (2) AU2002259309B2 (no)
BR (1) BR0210101A (no)
CA (1) CA2447732A1 (no)
CO (1) CO5540294A2 (no)
EA (1) EA007530B1 (no)
HU (1) HUP0400006A2 (no)
IL (1) IL158800A0 (no)
MX (1) MXPA03010907A (no)
NO (1) NO20035317L (no)
NZ (1) NZ529877A (no)
PL (1) PL367267A1 (no)
SG (1) SG153647A1 (no)
WO (1) WO2002098416A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269603B1 (en) * 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NO20220050A1 (no) * 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
EP2591775A1 (en) * 2006-04-05 2013-05-15 Novartis AG Combinations comprising mtor inhibitors for treating cancer
HUE039643T2 (hu) * 2007-03-07 2019-01-28 Abraxis Bioscience Llc Rapamicin rákellenes szert és albumint tartalmazó nanorészecske
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20180128078A (ko) 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
DE69209183T2 (de) * 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP2269603B1 (en) * 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane

Also Published As

Publication number Publication date
IL158800A0 (en) 2004-05-12
WO2002098416A3 (en) 2003-03-13
EP1392286A2 (en) 2004-03-03
HUP0400006A2 (hu) 2004-04-28
SG153647A1 (en) 2009-07-29
JP2004532883A (ja) 2004-10-28
NO20035317L (no) 2003-12-22
CN1646120A (zh) 2005-07-27
AU2008202690A1 (en) 2008-07-10
WO2002098416A2 (en) 2002-12-12
EA200301319A1 (ru) 2004-04-29
CA2447732A1 (en) 2002-12-12
NZ529877A (en) 2006-08-31
KR20040025923A (ko) 2004-03-26
AU2002259309B2 (en) 2008-05-01
BR0210101A (pt) 2004-06-08
CO5540294A2 (es) 2005-07-29
MXPA03010907A (es) 2004-02-17
EA007530B1 (ru) 2006-10-27
KR100875611B1 (ko) 2008-12-24
NO20035317D0 (no) 2003-11-28
CN100496485C (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
HK1061204A1 (en) Antineoplastic combinations
HK1068337A1 (en) Thiopene- amd thiazolesulfonamides as antineoplastic agents
HK1066170A1 (en) 6-substitued pyrido-pyrimidines
GB0220353D0 (en) Putter-heads
ZA200603888B (en) Antineoplastic combinations
GB0111171D0 (en) Projictile
IL158800A0 (en) Antineoplastic combinations
GB0117506D0 (en) Imidazopyridinones
DE60223825D1 (en) Ethynylierungsverfahren
DE60226167D1 (en) Computersystem-e/a-knoten
GB0102319D0 (en) Light-diffuser
DE60206072D1 (en) Aroylpyridinone
EP1355643A4 (en) EPOXYVIBSANIN B
GB0108915D0 (en) Igloob
GB0124755D0 (en) Airfresh luminair
GB0107567D0 (en) Visor-demister
GB0108574D0 (en) Softee-foam golftee
GB0104363D0 (en) Slip-a-shoe
GB0110727D0 (en) Easiquilt
GB0110942D0 (en) Vita-tea
GB0104279D0 (en) Ad-wall
GB0111749D0 (en) System-647
GB0112702D0 (en) Sticki-strips
GB0115141D0 (en) Shavewave
AU146973S (en) Neckerchief

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)